secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002039
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics restructures pipeline, cuts headcount 25% to extend cash runway into 2026
--------------------------------------------------------------------------------

- De-prioritizes CNTY-103 (glioblastoma) and discovery program; focuses on CNTY-101, CNTY-102, CNTY-107.
- Reduces headcount by ~25%; closes labs in Seattle and Hamilton, consolidates research in Philadelphia.
- Extends cash runway into 2026; Phase 1 CNTY-101 enrollment expected imminently; partnered BMS programs unaffected.
- Hy Levitsky, President of R&D, resigns effective Jan 31, 2023; Luis Borges and Adrienne Farid assume responsibilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923002039/0001104659-23-002039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465923002039/tm232470d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer